GNI Group Ltd.
Notice Regarding the Agreement for Full Subsidiarization of Cullgen Inc. by Consolidated Subsidiary Gyre Therapeutics, Inc.
Gyre Therapeutics has signed an acquisition agreement to make consolidated subsidiary Cullgen Inc. a wholly-owned subsidiary for approximately USD 300 million (approx. JPY 47 billion), with completion planned for early Q2 2026.
Key Figures
- Acquisition Price: Approximately USD 300 million (approx. JPY 47 billion)
- Scheduled Completion Date: Early Q2 2026
- Gyre Therapeutics Ownership Ratio: 70% (including Gyre Pharmaceuticals)
AI要約
Overview of the Acquisition
Gyre Therapeutics, Inc., a consolidated subsidiary of GNI Group Corporation, has entered into an acquisition agreement to make Cullgen Inc., also a consolidated subsidiary, a wholly-owned subsidiary. The acquisition will be conducted entirely by stock swap, with the transaction value estimated at approximately USD 300 million (approx. JPY 47 billion). The acquisition is expected to be completed in early Q2 2026. After the acquisition, Cullgen will become a wholly-owned subsidiary of Gyre Therapeutics and operate as a biopharmaceutical company based in the United States and China, covering the entire value chain from drug discovery to manufacturing and commercialization.
Future Outlook and Organizational Structure
Following the acquisition, Ping Zhang, the current Interim CEO and Executive Chairman of Gyre Therapeutics, will continue to serve as Executive Chairman, while Ying Luo, the current CEO of Cullgen, is expected to be appointed President and CEO of Gyre Therapeutics. This transaction is subject to usual regulatory approvals, and details will be promptly disclosed upon obtaining necessary approvals. This transaction constitutes a reorganization among consolidated subsidiaries and will not affect the consolidation scope.
